Zolfas
Zolfas Uses, Dosage, Side Effects, Food Interaction and all others data.
Zolfas is indicated in the treatment of the following serious infections-
Respiratory Tract Infections: Due to S. pneumoniae, Klebsiella, H. influenzae, S. aureus and group A beta-hemolytic streptococci. Zolfas is effective in the eradication of streptococci from the nasopharynx.
Urinary Tract Infections: Due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci .
Skin and Skin Structure Infections: Due to S. aureus, group A beta-hemolytic streptococci, and other strains of streptococci .
Biliary Tract Infections: Due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species and S. aureus .
Bone and Joint Infections: Due to S. aureus.
Genital Infections: Due to E . coli, P . mirabilis, Klebsiella species, and some strains of enterococci .
Septicemia: Due to S. pneumoniae, S. aureus, P. mirabilis, E. coli, and Klebsiella species .
Trade Name | Zolfas |
Availability | Prescription only |
Generic | Cefazolin |
Cefazolin Other Names | Cefamezin, Cefazolin, Cefazolina, Cefazoline, Cefazolinum, Cephamezine, Cephazolidin, Cephazolin, Cephazoline |
Related Drugs | amoxicillin, doxycycline, ciprofloxacin, cephalexin, metronidazole, azithromycin, clindamycin, ceftriaxone, levofloxacin, Augmentin |
Type | |
Formula | C14H14N8O4S3 |
Weight | Average: 454.507 Monoisotopic: 454.030013046 |
Protein binding | 74-86% |
Groups | Approved |
Therapeutic Class | |
Manufacturer | |
Available Country | Philippines |
Last Updated: | September 19, 2023 at 7:00 am |
![Zolfas Zolfas](https://www.medicinesfaq.com/media/png/zolfas.png)
Uses
Zolfas is a 1st generation semi-synthetic cephalosporin antibiotic for parenteral administration. It comes in a white to yellowish powder for injection form
Zolfas is also used to associated treatment for these conditions: Bacterial Infections, Bacterial Urinary Tract Infections, Biliary tract infection bacterial, Bloodstream Infections, Bone and Joint Infections, Catheter-related Bloodstream Infection (CRBSI) NOS, Community Acquired Pneumonia (CAP), Endocarditis, Epididymitis, Genital infection, Infective Endocarditis, Osteoarticular Infections, Postoperative Infections, Prostatitis, Respiratory Tract Infection Bacterial, Skin and Soft Tissue Infections, Skin and Subcutaneous Tissue Bacterial Infections, Surgical Site Infections, Susceptible infections, Perioperative infection, Antibiotic pre-surgical prophylaxis
How Zolfas works
In vitro tests demonstrate that the bactericidal action of cephalosporins results from inhibition of cell wall synthesis. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins.
Dosage
Zolfas dosage
Usual Adult Dosage
• For moderate to severe infection dose is 500 mg to 1 gm and frequency is every 6 to 8 hours
• For mild infections caused by Gram positive cocci dose is 250 mg to m00 mg and frequency is every 8 hours
• For acute uncomplicated urinary tract infection dose is 1 gm and frequency is every 12 hours
• For pneumococcal pneumonia dose is 500 gm and frequency is every 12 hours
• For severe life threatening infections dose is 1 gm to 1.5 gm and frequency is every 6 hours
Perioperative Prophylactic dose: To prevent postoperative infection, the recommended doses are: I. 1 gm IV or IM administered 1/2 hour to 1 hour prior to the start of surgery II . For lengthy surgery (e.g. 2 hours or more), 500 mg to 1 gm IV or IM during surgery III. 500 mg to 1 gm IV or IM every 6 to 8 hours for 24 hours postoperatively
Intramuscular Administration: Reconstitute vials with sterile Water for Injection. Shake well until dissolved. Zolfas should be injected into a large muscle mass
Intravenous Administration: For direct injection reconstitution, dilute vials with approximately 10 ml Sterile Water for Injection for 500 mg and 1 gm. Inject the solution slowly over 3 to 5 minutes. For continuous infusion dilute reconstituted in 50 to 100 mL of one of the following solutions: 0.9% Sodium Chloride Injection,5% or 10% Dextrose Injection, 5% Dextrose and 0 .9% Sodium Chloride Injection.
Pediatric Dosage: In pediatric patients, a total daily dosage of 25 to 50 mg per kg of body weight, divided into 3 or 4 equal doses, is effective for most mild to moderately severe infections. Total daily dosage may be increased to 100 mg per kg of body weight for severe infections. Since safety of Zolfas use in infants has not been established, it is not recommended
Side Effects
Swelling, redness, pain, or soreness at the injection site may occur. This medication may also rarely cause loss of appetite, nausea, vomiting, diarrhea or headache
Precaution
When Zolfas is administered to patients with impaired renal function, a lower daily dosage is required or otherwise, seizures may occur. it should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.
Food Interaction
No interactions found.Zolfas Hypertension interaction
[Moderate] Parenteral cefazolin sodium contains approximately 46 mg (2 mEq) of sodium per each gram of cefazolin activity.
The sodium content should be considered in patients with conditions that may require sodium restriction, such as congestive heart failure, hypertension, and fluid retention.
Zolfas Drug Interaction
Unknown: epinephrine, epinephrine, hydromorphone, hydromorphone, lvp solution, enoxaparin, enoxaparin, acetaminophen / hydrocodone, sodium chloride, sodium chloride, acetaminophen, acetaminophen, acetaminophen / oxycodone, acetaminophen / oxycodone, acetaminophen, acetaminophen, cholecalciferol, cholecalciferol, ondansetron, ondansetron
Zolfas Disease Interaction
Major: colitisModerate: renal dysfunction, sodium, dialysis, liver disease, seizure disorders
Elimination Route
Not absorbed from GI tract. Must be administered parenterally. Peak serum concentrations attained 1-2 hours post intramuscular injection.
Half Life
The serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.
Elimination Route
Zolfas is present in very low concentrations in the milk of nursing mothers. Zolfas is excreted unchanged in the urine. In the first six hours approximately 60% of the drug is excreted in the urine and this increases to 70%-80% within 24 hours.
Pregnancy & Breastfeeding use
There are no adequate studies in pregnant women for this drug so this drug should be used during pregnancy only if clearly needed. Zolfas is present in very low concentrations in the milk of nursing mothers so caution should be exercised.
Interaction with other Medicine
Probenecid may decrease renal tubular secretion of Zolfas, when used concurrently, resulting in increased Zolfas blood levels
Innovators Monograph
You find simplified version here Zolfas
Zolfas contains Cefazolin see full prescribing information from innovator Zolfas Monograph, Zolfas MSDS, Zolfas FDA label